InsidersTradesSigma
Follow the Aerie Pharmaceuticals INC share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Aerie Pharmaceuticals INC has logged 47 insider filings. The latest transaction was disclosed on 21 November 2022 (Disposition). Among the most active insiders: LaRocca John. The full history is accessible without an account.
47
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€11m
11 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 November 2022
Declarations47 total
41,984 shares@ US$15.2589.0% of flowCommon StockSEC:0001209191-22-058189:0
280,244 shares@ US$15.2599.5% of flowCommon StockSEC:0001209191-22-058186:0
18,585 shares@ US$15.2597.2% of flowCommon StockSEC:0001209191-22-058160:0
16,095 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058172:0
7,995 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058188:0
11,495 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058176:0
215,783 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058154:0
16,095 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058191:0
16,095 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058165:0
53,585 shares@ US$15.2592.6% of flowCommon StockSEC:0001209191-22-058180:0
46,297 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058183:0
179 shares@ US$15.221.0% of flowCommon StockSEC:0001209191-22-055670:0
265 shares@ US$11.571.1% of flowCommon StockSEC:0001209191-22-045975:0
771 shares@ US$11.571.0% of flowCommon StockSEC:0001209191-22-045976:0
266 shares@ US$8.360.8% of flowCommon StockSEC:0001209191-22-042043:0
11,276 shares0Common StockSEC:0001209191-22-041174:0
6,245 shares0Common StockSEC:0001209191-22-036389:0
6,245 shares0Common StockSEC:0001209191-22-036397:0
6,245 shares0Common StockSEC:0001209191-22-036354:0
6,245 shares0Common StockSEC:0001209191-22-036403:0
6,245 shares0Common StockSEC:0001209191-22-036386:0
6,245 shares0Common StockSEC:0001209191-22-036394:0
19,015 shares0Common StockSEC:0001209191-22-020656:0
46,297 shares0Common StockSEC:0001209191-22-020653:0
19,015 shares0Common StockSEC:0001209191-22-020655:0
25 of 47 declarations
关于 Aerie Pharmaceuticals INC
Aerie Pharmaceuticals Inc. 是一家总部位于美国的眼科制药公司，在美国纳斯达克上市，股票代码为 AERI，后被 Alcon 收购。该公司围绕眼科疾病（尤其侧重于青光眼和高眼压症）疗法的发现、开发和商业化而建立。其商业模式植根于专科制药经济学：集中研发、狭窄的治疗特许经营权，以及将差异化科学转化为具有重要商业潜力的获批产品的目标。([sec.gov](https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm?utm_source=openai)) Aerie 成立于 2010 年代初期，总部设在北卡罗来纳州达勒姆，位于美国最强大的生命科学中心之一。随着时间的推移，该公司从一家开发阶段的眼科公司发展成为一家商业化阶段的参与者。其最知名的产品是 Rhopressa（奈塔舒地尔滴眼液），适用于降低开角型青光眼或高眼压症患者的眼内压升高，以及 Rocklatan，一种奈塔舒地尔和拉坦前列素的固定剂量组合。这些产品成为 Aerie 青光眼特许经营权的核心，也是其技术平台的主要证明。([sec.gov](https://www.sec.gov/Archives/edgar/data/1337553/000162828019013540/aeri10-qx93019.htm?utm_source=openai)) 从竞争角度来看，Aerie 通过高度专业化的眼科重点及其基于 ROCK 抑制剂的作用机制脱颖而出。这种专业化使其与大型多元化制药公司相比具有独特的地位，后者通常通过更广泛的产品组合而非更有针对性的创新进行竞争。Aerie 还通过许可和商业化合作寻求国际扩张，旨在将 Rhopressa 和 Rocklatan 的覆盖范围扩展到美国以外，同时利用合作伙伴的区域基础设施。([nasdaq.com](https://www.nasdaq.com/press-release/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressar-and-rocklatanr?utm_source=openai)) 除了青光眼，该公司还继续投资于视网膜疾病项目和缓释眼科技术，这反映了其建立更广泛眼科产品线的雄心。即便如此，最近的重大公司事件是 Alcon 收购 Aerie，这突显了其商业资产和研发能力的战略价值。对于投资者而言，Aerie 最好被理解为一家专业的美国纳斯达克眼科公司，它成功地将利基创新转化为对全球眼科护理领导者具有吸引力的有价值的特许经营权。([alcon.com](https://www.alcon.com/media-release/alcon-acquire-aerie-pharmaceuticals-inc-enhancing-its-ophthalmic-pharmaceutical/?utm_source=openai))
